Eu­ro­pean reg­u­la­tors rec­om­mend re­jec­tion of Mer­ck’s Covid-19 drug mol­nupi­ravir

Eu­ro­pean reg­u­la­tors rec­om­mend­ed the EMA re­ject Mer­ck’s Covid an­tivi­ral, say­ing that there’s not enough ev­i­dence it works in pa­tients.

Mer­ck and part­ner Ridge­back Bio­ther­a­peu­tics an­nounced the CHMP’s de­ci­sion on Fri­day.

The com­mit­tee re­fused to rec­om­mend the ap­proval of Lagevrio, al­so known as mol­nupi­ravir, by ini­tial­ly stat­ing that the re­view has been on­go­ing for more than a year. The com­mit­tee had sup­port­ed de­ci­sions from mem­ber states start­ing in No­vem­ber 2021, if they want­ed to con­sid­er ear­ly use of mol­nupi­ravir be­fore any po­ten­tial ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.